EWTX logo

EDGEWISE THERAPEUTICS INC

EWTXNASDAQ
πŸ† #1128 by market capEarnings Nov 4US Equity
$44.31β–Ό $0.28 (βˆ’0.63%)
Market closed Β· at close
1hβ€”
24hβ–Ό 0.6%
7dβ–Ό 1.5%
14dβ–² 11.5%
30dβ–² 7.4%
1yβ–² 231.4%
🏦Market Cap
$4.77B
Small Cap
πŸ“ˆRevenue Growth (YoY)
β€”
πŸ“ŠGross Margin
β€”
πŸ’΅FCF Margin
β€”
βš–οΈP/S Ratio
β€”
Otter Score
55
Weak

Trading Snapshot

Day Range
$43.88 – $44.84
52-Week Range
$12.30 – $48.40
Volume
$3.22B
Avg Volume
$2.23B
Shares Outstanding
107.6M
Next Earnings
Oct 5, 2026

Fundamentals Snapshot

Annual Revenue
$822M
Last Q Revenue
$224M
P/E Ratio
β€”
P/S Ratio
β€”
EPS (TTM)
$-1.85
Dividend Yield
β€”

Why Investors Own EWTX

  • βœ“High-growth profile β€” revenue up +27.6% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 73% gross margin and 18% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)
$822Mβ–² +28.0% YoY
Gross Margin (TTM)
73.0%β–² +0.4% YoY
Operating Income (TTM)
$196Mβ–² +28.0% YoY
Free Cash Flow (TTM)
$145Mβ–² +28.0% YoY

About EDGEWISE THERAPEUTICS INC

A company profile for EDGEWISE THERAPEUTICS INC isn’t available yet β€” check back soon.

🦦

Otter Score Breakdown

β“˜
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
Overall Score
Weak
55/100

Analyst Ratings

β“˜
Consensus
Buy
19 analysts
Strong Buy7
Buy9
Hold3
Sell0
Strong Sell0
Ratings as of Aug 2026

Latest News & Updates

πŸš€
BenzingaΒ·15h ago

Goldman Sachs Maintains Neutral on Edgewise Therapeutics, Raises Price Target to $36

Goldman Sachs analyst Paul Choi maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Neutral and raises the price target from $32 to $36.

πŸ›°οΈ
BenzingaΒ·5d ago

Edgewise Therapeutics Q2 EPS $(0.53) Misses $(0.47) Estimate

Edgewise Therapeutics (NASDAQ:EWTX) reported quarterly losses of $(0.53) per share which missed the analyst consensus estimate of $(0.47) by 12.77 percent. This is a 55.88 percent decrease over losses of $(0.34) per

SeekingAlphaΒ·21d ago

Tracking Baker Brothers Portfolio: Q1 2026 Update

Baker BrothersҀ™ Q1 2026 13F: $17.42B biotech portfolio, top holdings & key buys/sells. Click here to read more.

πŸš€
BenzingaΒ·22d ago

Evercore ISI Group Maintains Outperform on Edgewise Therapeutics, Raises Price Target to $55

Evercore ISI Group analyst Cory Kasimov maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Outperform and raises the price target from $45 to $55.